ITEM VIEW

AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART) - An African perspective

dc.contributor.authorSissolak, G.
dc.contributor.authorAbayomi, E. A.
dc.contributor.authorJacobs, P.
dc.date.accessioned2011-05-15T16:18:15Z
dc.date.available2011-05-15T16:18:15Z
dc.date.issued2007
dc.identifier.citationTransfusion and Apheresis Science
dc.identifier.citation37
dc.identifier.citation1
dc.identifier.issn14730502
dc.identifier.other10.1016/j.transci.2007.04.010
dc.identifier.urihttp://hdl.handle.net/10019.1/14579
dc.description.abstractThe intermediate to high grade B-cell non-Hodgkin lymphomas are now one of three malignant AIDS defining conditions. The others being Kaposi's sarcoma and cervical carcinoma. While co-infection with oncogenic agents including the human herpes 8 or Epstein-Barr virus offer targets in preventive treatment strategies for these AIDS defining lymphomas (ADL), administration of highly active antiretroviral therapy leading to immune reconstitution permits use of standard or even high-dose cytotoxic drug regimens with curative intent. It is not certain whether this should be done concomitantly or sequentially. Additional benefit may derive from infusional or high-dose chemotherapy regimens depending on the histological subtype while use of monoclonal antibodies such as rituximab or immunohaematopoietic stem cell transplantation needs to be further evaluated within controlled studies. Socio-economic considerations have an impact especially in resource limited settings while availability of tools for appropriate geno-phenotypic diagnosis and immunological monitoring such as the CD4 cell count will play an important role in the risk stratification as well as disease management. While it is generally accepted that the impact of HAART has an overall benefit both in incidence and treatment outcome in ADL, the expanded access to HAART programs are falling short of all targets in Africa. Accordingly focus is given to some of these controversies, including epidemiology, pathogenesis, clinical features, therapeutic options and ethical considerations. © 2007 Elsevier Ltd. All rights reserved.
dc.subjectantiretrovirus agent
dc.subjectcyclophosphamide
dc.subjectcytarabine
dc.subjectdoxorubicin
dc.subjectetoposide
dc.subjectifosfamide
dc.subjectmethotrexate
dc.subjectprednisone
dc.subjectrituximab
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectvincristine
dc.subjectzidovudine
dc.subjectacquired immune deficiency syndrome
dc.subjectAfrica
dc.subjectarticle
dc.subjectB cell lymphoma
dc.subjectBurkitt lymphoma
dc.subjectcancer chemotherapy
dc.subjectCD4+ T lymphocyte
dc.subjectdisease association
dc.subjectEpstein Barr virus
dc.subjectgenotype
dc.subjecthematopoietic stem cell transplantation
dc.subjecthighly active antiretroviral therapy
dc.subjecthuman
dc.subjectHuman herpesvirus 8
dc.subjectHuman immunodeficiency virus infection
dc.subjectlymphoma
dc.subjectnonhodgkin lymphoma
dc.subjectphenotype
dc.subjectsocioeconomics
dc.subjecttreatment outcome
dc.subjectAcquired Immunodeficiency Syndrome
dc.subjectAfrica
dc.subjectAntibodies, Monoclonal
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectAntiretroviral Therapy, Highly Active
dc.subjectCD4 Lymphocyte Count
dc.subjectFemale
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectHerpesvirus 4, Human
dc.subjectHerpesvirus 8, Human
dc.subjectHumans
dc.subjectLymphoma, B-Cell
dc.subjectMale
dc.subjectSarcoma, Kaposi
dc.subjectSocioeconomic Factors
dc.subjectUterine Cervical Neoplasms
dc.titleAIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART) - An African perspective
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW